Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Glaukos Corporation

In a report released today, Danielle Antalffy from UBS maintained a Buy rating on Glaukos, with a price target of $150.00. Antalffy covers the Heal...

UBS Keeps Their Buy Rating on Glaukos (GKOS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Capricor Therapeutics (CAPR – Research Report), Tvar...

Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Tvardi Therapeutics (TVRD)

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Glaukos today and set a price target of $160.00. According to TipRanks, Stephan i...

Stifel Nicolaus Remains a Buy on Glaukos (GKOS)

Glaukos Corp. ($GKOS) announced an update on their ongoing clinical study. Glaukos Corp. (GKOS) is running a new late-stage study called “Multicent...

Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV – Research Report) and Glaukos (GKOS – ...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS)

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Glaukos, with a price target of $122.00. According to TipRa...

Wells Fargo Sticks to Its Buy Rating for Glaukos (GKOS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Glaukos (GKOS – Research Report), Rapid Micro Biosys...

Current Quarter	$-0.24	Next Quarter	$-0.16
Current Year	$-0.86	Next Year	$-0.33
QoQ Growth	+33.3%	YoY Growth	+61.6%
3Y EPS CAGR	-37.3%	Target Price	$132.71
Consensus	Buy	Upside	+13.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GKOS	$117.03	-0.38%	265.44K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GKOS	$117.03	-0.4%	265.44K
3
4
5
6

GKOS

GKOS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Glaukos Corporation Data in Excel

Get Glaukos Corporation Data in Excel